BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alanazi MM, Eissa IH, Alsaif NA, Obaidullah AJ, Alanazi WA, Alasmari AF, Albassam H, Elkady H, Elwan A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1760-82. [PMID: 34340610 DOI: 10.1080/14756366.2021.1956488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Eissa IH, El-Haggar R, Dahab MA, Ahmed MF, Mahdy HA, Alsantali RI, Elwan A, Masurier N, Fatahala SS. Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers. J Enzyme Inhib Med Chem 2022;37:1587-99. [PMID: 35637622 DOI: 10.1080/14756366.2022.2081844] [Reference Citation Analysis]
2 Alanazi MM, Elkady H, Alsaif NA, Obaidullah AJ, Alanazi WA, Al-hossaini AM, Alharbi MA, Eissa IH, Dahab MA. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. Journal of Molecular Structure 2022;1253:132220. [DOI: 10.1016/j.molstruc.2021.132220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
3 Yousef RG, Ibrahim A, Khalifa MM, Eldehna WM, Gobaara IMM, Mehany ABM, Elkaeed EB, Alsfouk AA, Metwaly AM, Eissa IH. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J Enzyme Inhib Med Chem 2022;37:1389-403. [PMID: 35577416 DOI: 10.1080/14756366.2022.2070744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Alsaif NA, Elwan A, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari AF, Albassam H, Mahdy HA, Taghour MS. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Mol Divers 2021. [PMID: 34460053 DOI: 10.1007/s11030-021-10303-6] [Reference Citation Analysis]
5 Azab AE, Alesawy MS, Eldehna WM, Elwan A, Eissa IH. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation. Arch Pharm (Weinheim) 2022;:e2200133. [PMID: 35822666 DOI: 10.1002/ardp.202200133] [Reference Citation Analysis]
6 Eissa IH, Khalifa MM, Elkaeed EB, Hafez EE, Alsfouk AA, Metwaly AM. In Silico Exploration of Potential Natural Inhibitors against SARS-Cov-2 nsp10. Molecules 2021;26:6151. [PMID: 34684735 DOI: 10.3390/molecules26206151] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ran F, Li W, Qin Y, Yu T, Liu Z, Zhou M, Liu C, Qiao T, Li X, Yousef RG, Eissa IH, Khalifa MM. Inhibition of Vascular Smooth Muscle and Cancer Cell Proliferation by New VEGFR Inhibitors and Their Immunomodulator Effect: Design, Synthesis, and Biological Evaluation. Oxid Med Cell Longev 2021;2021:8321400. [PMID: 34745424 DOI: 10.1155/2021/8321400] [Reference Citation Analysis]
8 Hagras M, Saleh MA, Ezz Eldin RR, Abuelkhir AA, Khidr EG, El-Husseiny AA, El-Mahdy HA, Elkaeed EB, Eissa IH. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies. J Enzyme Inhib Med Chem 2022;37:380-96. [PMID: 34923885 DOI: 10.1080/14756366.2021.2015342] [Reference Citation Analysis]
9 Elkady H, Elwan A, El-Mahdy HA, Doghish AS, Ismail A, Taghour MS, Elkaeed EB, Eissa IH, Dahab MA, Mahdy HA, Khalifa MM. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J Enzyme Inhib Med Chem 2022;37:397-410. [PMID: 34961427 DOI: 10.1080/14756366.2021.2015343] [Reference Citation Analysis]
10 Abdallah AE, Alesawy MS, Eissa SI, El-fakharany EM, Kalaba MH, Sharaf MH, Abo Shama NM, Mahmoud SH, Mostafa A, Al-karmalawy AA, Elkady H. Design and synthesis of new 4-(2-nitrophenoxy)benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. New J Chem 2021;45:16557-71. [DOI: 10.1039/d1nj02710g] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 25.0] [Reference Citation Analysis]
11 Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari A, Albassam H, Dahab MA, Mahdy HA. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorg Med Chem 2021;46:116384. [PMID: 34479065 DOI: 10.1016/j.bmc.2021.116384] [Reference Citation Analysis]
12 Alesawy MS, Elkaeed EB, Alsfouk AA, Metwaly AM, Eissa IH. In Silico Screening of Semi-Synthesized Compounds as Potential Inhibitors for SARS-CoV-2 Papain-like Protease: Pharmacophoric Features, Molecular Docking, ADMET, Toxicity and DFT Studies. Molecules 2021;26:6593. [PMID: 34771004 DOI: 10.3390/molecules26216593] [Reference Citation Analysis]
13 Alsaif NA, Mahdy HA, Alanazi MM, Obaidullah AJ, Alkahtani HM, Al-Hossaini AM, Al-Mehizi AA, Elwan A, Taghour MS. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. Arch Pharm (Weinheim) 2021;:e2100359. [PMID: 34862634 DOI: 10.1002/ardp.202100359] [Reference Citation Analysis]
14 Belal A, Abdel Gawad NM, Mehany ABM, Abourehab MAS, Elkady H, Al-Karmalawy AA, Ismael AS. Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors. J Enzyme Inhib Med Chem 2022;37:1884-902. [PMID: 35801486 DOI: 10.1080/14756366.2022.2096019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Taghour MS, Mahdy HA, Gomaa MH, Aglan A, Eldeib MG, Elwan A, Dahab MA, Elkaeed EB, Alsfouk AA, Khalifa MM, Eissa IH, Elkady H. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation. J Enzyme Inhib Med Chem 2022;37:2063-77. [PMID: 35875937 DOI: 10.1080/14756366.2022.2103552] [Reference Citation Analysis]
16 Elkaeed EB, Youssef FS, Eissa IH, Elkady H, Alsfouk AA, Ashour ML, El Hassab MA, Abou-seri SM, Metwaly AM. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease. IJMS 2022;23:6912. [DOI: 10.3390/ijms23136912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
17 Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk AA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches. Processes 2022;10:1391. [DOI: 10.3390/pr10071391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Elkaeed EB, Elkady H, Belal A, Alsfouk BA, Ibrahim TH, Abdelmoaty M, Arafa RK, Metwaly AM, Eissa IH. Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs. Processes 2022;10:530. [DOI: 10.3390/pr10030530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
19 Alanazi MM, Elkady H, Alsaif NA, Obaidullah AJ, Alkahtani HM, Alanazi MM, Alharbi MA, Eissa IH, Dahab MA. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv 2021;11:30315-28. [PMID: 35493991 DOI: 10.1039/d1ra05925d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Taghour MS, Elkady H, Eldehna WM, El-Deeb NM, Kenawy AM, Elkaeed EB, Alsfouk AA, Alesawy MS, Metwaly AM, Eissa IH. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J Enzyme Inhib Med Chem 2022;37:1903-17. [PMID: 35801403 DOI: 10.1080/14756366.2022.2085693] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yousef RG, Eldehna WM, Elwan A, Abdelaziz AS, Mehany ABM, Gobaara IMM, Alsfouk BA, Elkaeed EB, Metwaly AM, Eissa IH. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2. Molecules 2022;27:4079. [DOI: 10.3390/molecules27134079] [Reference Citation Analysis]